Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue

Freilich, Ronnie J.; Kraus, Dennis H.; Budnick, Amy; Bayer, Lisa A.; Finlay, Jonathan L.

doi:10.1002/(sici)1096-911x(199602)26:2<95::aid-mpo5>3.0.co;2-p

Cited by 48 publications

(24 citation statements)

References 30 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the varying susceptibility to ototoxic drugs, and the differences among drug regimens, this was not a surprising finding. In general, such a varied pattern of hearing loss results are in agreement with studies such as Freilich, Kraus, Budnick, Bayer, and Finlay (1996), Hale et al (1999), and Pasic and Dobie (1991).…”

Section: Discussionsupporting

confidence: 88%

DPOAE Changes in Young Children With Confirmed Hearing Loss Due to Ototoxicity

Beahan¹,

Reichman²,

Kei³

et al. 2006

Australian and New Zealand Journal of Audiology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 88%

DPOAE Changes in Young Children With Confirmed Hearing Loss Due to Ototoxicity

Beahan¹,

Reichman²,

Kei³

et al. 2006

Australian and New Zealand Journal of Audiology

View full text Add to dashboard Cite

“…Prior reports of the preparative regimen for ABMT used in our study have not been associated with hearing loss, although most of the patients were not heavily pre-treated with platinum agents and were older than our study patients (Wiley, personal communication). A recent study by Freilich and co-workers 25 of a small cohort of children receiving experimental treatment for malignant brain tumors reports deterioration of hearing in five of the 11 patients following consolidation therapy including highdose carboplatin. Of note, seven of the 11 patients had highfrequency hearing loss following induction therapy with cisplatin.…”

Section: Discussionmentioning

confidence: 99%

Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma

Parsons

Neault

Lehmann

et al. 1998

Bone Marrow Transplant

101

View full text Add to dashboard Cite

Summary:Children with neuroblastoma receiving high-dose carboplatin as part of their conditioning regimen for autologous marrow transplantation have a high incidence of speech frequency hearing loss. We evaluated hearing loss in 11 children with advanced stage neuroblastoma who underwent autologous marrow transplantation, following a conditioning regimen containing high-dose carboplatin (2 g/m 2 , total dose). Audiometric evaluations were obtained at diagnosis, prior to and following transplant. Exposure to other known ototoxins also was assessed. All patients sustained worsening of hearing following high-dose carboplatin. Nine of the 11 children (82%) had evidence of speech frequency hearing loss post transplant for which hearing aids were recommended (grades 3-4). Three of the nine children had speech frequency loss prior to transplant which progressed following transplant. The entire group was heavily pre-treated with platinum-containing chemotherapy pre-BMT and had extensive exposure to other ototoxins, including aminoglycoside antibiotics, diuretics, and noise exposure -all of which could have exacerbated the effects of carboplatin. High-dose carboplatin is ototoxic, particularly in patients who have been primed with previous platinum therapy or other ototoxic agents. We conclude that further efforts are needed to monitor and minimize this complication. In cases where hearing loss is inevitable due to cumulative ototoxic exposures, families need to be adequately prepared for the tradeoffs of potentially curable therapy. Keywords: ototoxicity; neuroblastoma; carboplatin The platinum-containing chemotherapeutic agents play a key role in the treatment of selected pediatric solid tumors. Carboplatin (cis-diammine I, I-cyclobutane dicarboxylato platinum II (CBDCA)), an analogue of cisplatin (cis-dichlorodiammine platinum II (CDDP)), was introduced to clini- 1 Early reports indicated that the incidence of ototoxicity following carboplatin administration might also be lower than that after cisplatin use.1-3 These studies revealed that myelosuppression, not nephrotoxicity, was the dose-limiting toxicity for carboplatin. At the maximum tolerable doses for myelosuppression, single-agent phase I and II studies of carboplatin in adults found a 15% incidence of subclinical hearing loss and a 1% incidence of clinical ototoxicity, primarily manifested as tinnitus.2,3 Similarly, severe hearing loss in children was relatively infrequent. 4 In contrast, the reported incidence of ototoxicity with cisplatin, administered at conventional doses, has ranged from 4 to 91% in different studies.5 Moreover, when hearing loss occurs, it is predominantly in the high-frequency range, although speech frequencies are also affected -occasionally independent of dose or dose rate. The overall incidence of high-frequency hearing loss following cisplatin administration ranges from 30 to 50%; progressive involvement of the speech range frequencies has been reported at 15-20%.

show abstract

“…However, hearing loss has been reported in about half of children who received carboplatin-containing conditioning regimens. 45 Neurological and intellectual functions in children who received HDC but not radiotherapy during their first years of life were either in the low average or only moderately impaired. 46 Second cancers are reported in persons treated with HDC/AuHCR for cancers other than brain tumors.…”

Section: Myeloablative Chemotherapy For Cns Tumors a Marachelian Et Almentioning

confidence: 99%

Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors

Marachelian

Butturini

Finlay

2008

Bone Marrow Transplant

View full text Add to dashboard Cite

Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue has been evaluated in the treatment of children and young adults with brain tumors for whom conventional therapy is either too toxic (for example, radiotherapy in infants) or ineffective (for example, recurrent malignant tumors). With this strategy, myeloablative chemotherapy is administered to patients after initial surgery, and standard-dose chemotherapy. The success of myeloablative chemotherapy depends on the histological type of tumor, extent of disease and of surgical resection, and response to prior chemotherapy. Here, we review results of myeloablative chemotherapy with hematopoietic progenitor cell rescue in brain tumors of different histologies.

show abstract

Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue

Cited by 48 publications

References 30 publications

DPOAE Changes in Young Children With Confirmed Hearing Loss Due to Ototoxicity

DPOAE Changes in Young Children With Confirmed Hearing Loss Due to Ototoxicity

Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma

Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors

Contact Info

Product

Resources

About